ULTRALIFE CORP Income Taxes Disclosure
Note 7 - Income Taxes
For the years ended December 31, 2025, and 2024, we recognized an income tax (benefit) provision of ($2,447) and $1,892, respectively.
|
Year ended December 31, |
||||||||
|
2025 |
2024 |
|||||||
|
Current: |
||||||||
|
Federal |
$ | 12 | $ | - | ||||
| State | 48 | 50 | ||||||
|
Foreign |
34 |
610 | ||||||
|
94 |
660 | |||||||
|
Deferred: |
||||||||
|
Federal |
(1,802 |
) | 1,313 | |||||
| State | (248 | ) | 58 | |||||
|
Foreign |
(491 |
) | (139 | ) | ||||
|
(2,541 |
) | 1,232 | ||||||
|
Total income tax (benefit) provision |
$ | (2,447 | ) | $ | 1,892 | |||
Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amount used for income tax purposes. Significant components of our deferred tax assets and liabilities are as follows:
|
December 31, |
||||||||
|
2025 |
2024 |
|||||||
|
Deferred tax assets: |
||||||||
|
Net operating loss carryforwards |
$ | 4,809 | $ | 5,817 | ||||
|
Research and development |
5,448 |
4,894 | ||||||
|
Tax credit carryforwards |
3,448 |
3,180 | ||||||
|
Inventory reserves |
2,991 |
2,859 | ||||||
|
Intangible assets |
610 |
1,678 | ||||||
| Lease Liability | 728 | 905 | ||||||
|
Accrued expenses and other |
1,318 |
1,542 | ||||||
|
Total deferred tax assets |
19,352 |
20,875 | ||||||
|
Valuation allowance for deferred tax assets |
(2,530 |
) | (2,404 | ) | ||||
|
Net deferred tax assets |
16,822 |
18,471 | ||||||
|
Deferred tax liabilities: |
||||||||
|
Intangible assets |
(5,619 |
) | (9,480 | ) | ||||
|
Property, plant and equipment |
(980 |
) | (1,113 | ) | ||||
| Right of use asset | (729 | ) | (908 | ) | ||||
|
Total deferred tax liabilities |
(7,328 |
) | (11,501 | ) | ||||
|
Net deferred tax assets |
$ | 9,494 | $ | 6,970 | ||||
Net deferred tax assets (liabilities) are comprised of the following balance sheet amounts:
|
December 31, |
||||||||
|
2025 |
2024 |
|||||||
|
Deferred tax assets, net |
$ | 10,494 | $ | 8,413 | ||||
|
Deferred tax liabilities |
(1,000 |
) | (1,443 | ) | ||||
| $ | 9,494 | $ | 6,970 | |||||
For financial reporting purposes, net (loss) income from continuing operations before income taxes is as follows:
|
Year ended December 31, |
||||||||
|
2025 |
2024 |
|||||||
|
United States |
$ | (5,863 | ) | $ | 7,044 | |||
|
Foreign |
(2,535 |
) | 1,257 | |||||
| $ | (8,398 | ) | $ | 8,301 | ||||
The provision for income taxes differs from the amount of income tax determined by applying the applicable U.S. statutory federal income tax rate to income from continuing operations before income taxes as follows under the guidance in ASU 2023-09 the Company adopted on a prospective basis:
|
Year ended December 31, 2025 |
||||||||
|
Federal statutory income tax rate |
$ | (1,763 | ) | 21.0 | % | |||
|
State and local income taxes, net of federal income tax effect (a) |
(204 | ) | 2.4 | |||||
|
Nontaxable or nondeductible items: |
||||||||
|
Equity compensation |
136 | (1.6 | ) | |||||
|
Nontaxable refund credit |
(296 | ) | 3.5 | |||||
|
Other |
14 | (0.2 | ) | |||||
| Other reconciling items | (127 | ) | 1.5 | |||||
|
Tax credits: |
||||||||
|
R&D |
(267 | ) | 3.2 | |||||
|
Cross-border tax laws: |
(20 | ) | 0.2 | |||||
|
Foreign tax effects: |
||||||||
|
China |
||||||||
|
R&D deduction |
(103 | ) | 1.2 | |||||
|
Other |
(8 | ) | 0.1 | |||||
|
Hong Kong |
||||||||
|
Tax rate differential |
131 | (1.5 | ) | |||||
|
Canada |
||||||||
| Tax rate differential | 164 | (2.0 | ) | |||||
| Provincial taxes | (303 | ) | 3.6 | |||||
| Change in functional currency | 170 | (2.0 | ) | |||||
|
Other |
20 | (0.2 | ) | |||||
|
Other foreign jurisdictions |
9 | (0.1 | ) | |||||
|
Effective income tax rate |
$ | (2,447 | ) | 29.1 | % | |||
|
a. |
State taxes and state tax adjustments in Florida and Virginia made up the majority (greater than 50%) of the tax effect in this category. |
The provision for income taxes differs from the amount of income tax determined by applying the applicable U.S. statutory federal income tax rate to income from continuing operations before income taxes as follows under the prior guidance:
|
Year ended December 31, |
||||
|
2024 |
||||
|
Statutory income tax rate |
21.0 | % | ||
|
Increase (decrease) in tax provision resulting from: |
||||
|
Equity compensation |
0.5 | |||
|
Global intangible low-taxed income |
0.7 | |||
|
China R&D deduction |
(1.1 | ) | ||
|
Income tax credits |
(3.6 | ) | ||
|
Tax rate changes |
(0.1 | ) | ||
|
Foreign exchange loss |
0.8 | |||
|
Foreign tax rates |
2.3 | |||
|
States taxes |
1.1 | |||
|
Transaction costs |
0.7 | |||
|
Other |
0.5 | |||
|
Effective income tax rate |
22.8 | % | ||
Upon adoption of ASU 2023-09, as described in Note 1, cash paid for income taxes, net of refunds was as follows:
|
Year ended December 31, |
||||
|
2025 |
||||
|
Federal |
$ | 34 | ||
|
State |
49 | |||
|
Foreign: |
||||
|
Canada |
126 | |||
|
China |
- | |||
|
United Kingdom |
(91 | ) | ||
|
India |
29 | |||
|
Total foreign |
64 | |||
|
Total income taxes paid, net of refunds |
$ | 147 | ||
As of December 31, 2025, it was concluded that it is more likely than not that our U.S. deferred tax assets will be fully realized based on management’s assessment. In evaluating the realizability of our U.S. deferred tax assets, management considered all available evidence, both positive and negative, weighted based on objective verifiability. Our assessment also considered our ability to fully utilize before expiration our domestic net operating loss carryforwards, which begin to expire in 2031, and our federal general business tax credit carryforwards, which begin to expire in 2028. As of December 31, 2025, our federal net operating loss carryforwards, state net operating loss carryforwards, and federal general business tax credit carryforwards were $8,800, $5,100 and $3,400, respectively.
As of December 31, 2025, for certain past operations in the U.K., we continue to report a valuation allowance for net operating loss carryforwards of approximately $10,100, nearly all of which can be carried forward indefinitely. Management has concluded that utilization of the U.K. net operating losses may be limited due to the change in the past U.K. operation, and that they cannot currently be used to reduce taxable income of our other U.K. subsidiary, Accutronics Ltd. There are no other deferred tax assets related to the past U.K. operations.
As of December 31, 2025, we have recognized a valuation allowance against our other foreign deferred tax assets, including net operating loss carryforwards of $1,300 which expire in 2029 through 2035, as we believe that it is more likely than not that they will be fully realized.
There were unrecognized tax benefits related to uncertain tax positions at December 31, 2025, and 2024.
As of December 31, 2025, the Company maintains its assertion that all foreign earnings will be indefinitely reinvested in those operations, other than earnings generated in the U.K.
As a result of our operations, we file income tax returns in various jurisdictions including U.S. federal, U.S. state and foreign jurisdictions. We are routinely subject to examination by taxing authorities in these various jurisdictions. Our U.S. tax matters for through 2024 remain subject to IRS examination. Our U.S. tax matters for 2005-2007, 2009, and 2011-2015 also remain subject to IRS examination due to the remaining availability of net operating loss carryforwards generated in those years. Our U.S. tax matters for through 2024 remain subject to examination by various state and local tax jurisdictions. Our tax matters for the years through 2024 remain subject to examination by the respective foreign tax jurisdiction authorities.
Want the next ULTRALIFE CORP income taxes disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment ULTRALIFE CORP's next filing hits EDGAR. No credit card, your email never gets sold.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 23, 2026 | Showing above |
| 2024 | Apr 1, 2025 | |
| 2023 | Mar 21, 2024 | |
| 2022 | Mar 31, 2023 | |
| 2021 | Mar 8, 2022 | |
| 2020 | Feb 4, 2021 | |
| 2019 | Feb 6, 2020 | |
| 2018 | Feb 7, 2019 | |
| 2017 | Feb 8, 2018 | |
| 2016 | Feb 9, 2017 | |
| 2015 | Mar 2, 2016 | |
About Income Taxes Disclosures
The income tax disclosure reveals how much a company actually pays in taxes versus what the statutory rate would predict. Analysts focus on the effective tax rate (ETR) reconciliation, which breaks down every item driving the gap between the 21% federal rate and the company's reported ETR — including R&D credits, foreign rate differentials, and state taxes. Deferred tax assets (DTAs) and their valuation allowances signal management's confidence in future profitability: a rising allowance suggests the company doubts it can use accumulated tax benefits. Uncertain tax benefit (UTB) reserves quantify exposure to IRS challenges on aggressive positions.
Key signals to watch: sudden ETR drops without clear operational reasons, large increases in valuation allowances, growing UTB balances, and significant unremitted foreign earnings. Post-TCJA, pay attention to GILTI and BEAT provisions that affect multinational tax structures. Compare the cash taxes paid (from the cash flow statement) against the income tax provision to gauge earnings quality.